A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Christie Ballantyne, MD

Christie Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention Methodist DeBakey Heart Center Chief of the Section of Cardiovascular Research Baylor College of Medicine Director of Atherosclerosis Laboratory Professor of Medicine Baylor College of Medicine Houston, TX